Aim

A Phase III clinical trial in chILD (InPedILD)

OBJECTIVE: To evaluate the dose-exposure relationship and safety of nintedanib in children with fibrosing ILD

  • Multicenter, double-blind, randomized trial 1199-0337
  • ClinicalTrials.gov: NCT04093024
Header - Navigation Icon